262 related articles for article (PubMed ID: 24809288)
21. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
22. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.
Sang X; Han H; Poirier D; Lin SX
J Steroid Biochem Mol Biol; 2018 Oct; 183():80-93. PubMed ID: 29803725
[TBL] [Abstract][Full Text] [Related]
23. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells.
Zhang Y; Qian RQ; Li PP
Cancer Lett; 2009 Oct; 284(1):47-54. PubMed ID: 19419812
[TBL] [Abstract][Full Text] [Related]
24. Dual aromatase-steroid sulfatase inhibitors.
Woo LW; Bubert C; Sutcliffe OB; Smith A; Chander SK; Mahon MF; Purohit A; Reed MJ; Potter BV
J Med Chem; 2007 Jul; 50(15):3540-60. PubMed ID: 17580845
[TBL] [Abstract][Full Text] [Related]
25. Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.
Wood PM; Woo LW; Thomas MP; Mahon MF; Purohit A; Potter BV
ChemMedChem; 2011 Aug; 6(8):1423-38. PubMed ID: 21608133
[TBL] [Abstract][Full Text] [Related]
26. Intracrine mechanism of estrogen synthesis in breast cancer.
Suzuki T; Moriya T; Ishida T; Ohuchi N; Sasano H
Biomed Pharmacother; 2003 Dec; 57(10):460-2. PubMed ID: 14637389
[TBL] [Abstract][Full Text] [Related]
27. Aromatase inhibitors and their antitumor effects in model systems.
Brodie A; Lu Q; Liu Y; Long B
Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
[TBL] [Abstract][Full Text] [Related]
28. Steroid sulfatase inhibitors: their potential in the therapy of breast cancer.
Nussbaumer P; Billich A
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):507-28. PubMed ID: 16178776
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities.
Bubert C; Woo LW; Sutcliffe OB; Mahon MF; Chander SK; Purohit A; Reed MJ; Potter BV
ChemMedChem; 2008 Nov; 3(11):1708-30. PubMed ID: 18816537
[TBL] [Abstract][Full Text] [Related]
30. Estradiol as an anti-aromatase agent in human breast cancer cells.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):12-7. PubMed ID: 16413774
[TBL] [Abstract][Full Text] [Related]
31. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
Xu B; Kitawaki J; Koshiba H; Ishihara H; Kiyomizu M; Teramoto M; Kitaoka Y; Honjo H
Maturitas; 2007 Feb; 56(2):142-52. PubMed ID: 16962266
[TBL] [Abstract][Full Text] [Related]
33. The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
Ye L; Chan FL; Chen S; Leung LK
J Nutr Biochem; 2012 Oct; 23(10):1230-7. PubMed ID: 22209285
[TBL] [Abstract][Full Text] [Related]
34. Development of novel steroid sulfatase inhibitors. I. Synthesis and biological evaluation of biphenyl-4-O-sulfamates.
Okada M; Nakagawa T; Iwashita S; Takegawa S; Fujii T; Koizumi N
J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):141-8. PubMed ID: 14672734
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Wang M; Mickens J; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH
Steroids; 2009 Nov; 74(12):896-905. PubMed ID: 19559719
[TBL] [Abstract][Full Text] [Related]
36. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
37. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers.
Purohit A; Foster PA
J Endocrinol; 2012 Feb; 212(2):99-110. PubMed ID: 21859802
[TBL] [Abstract][Full Text] [Related]
38. Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach.
Singh Y; Jaswal S; Singh S; Verma SK; Thareja S
J Biomol Struct Dyn; 2023 Dec; 41(20):10604-10626. PubMed ID: 36510679
[TBL] [Abstract][Full Text] [Related]
39. Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro.
Stute P; Götte M; Kiesel L
Breast Cancer Res Treat; 2008 Apr; 108(3):363-74. PubMed ID: 17546497
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Stanway SJ; Purohit A; Woo LW; Sufi S; Vigushin D; Ward R; Wilson RH; Stanczyk FZ; Dobbs N; Kulinskaya E; Elliott M; Potter BV; Reed MJ; Coombes RC
Clin Cancer Res; 2006 Mar; 12(5):1585-92. PubMed ID: 16533785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
